Hologic, Inc. (HOLX) Director Elaine Ullian Sells 9,282 Shares
Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 9,282 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Hologic, Inc. (NASDAQ HOLX) traded up $0.24 during midday trading on Friday, reaching $39.96. The company had a trading volume of 2,092,406 shares, compared to its average volume of 2,739,979. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The stock has a market cap of $11,140.00, a P/E ratio of 19.61, a P/E/G ratio of 1.92 and a beta of 0.93. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.78.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 EPS. Hologic’s quarterly revenue was up 10.5% on a year-over-year basis. equities research analysts anticipate that Hologic, Inc. will post 2.12 earnings per share for the current year.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Needham & Company LLC reissued a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Friday, November 3rd. BidaskClub downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Bank of America Corporation reissued a “neutral” rating and set a $48.00 target price (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $45.00 target price (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Hologic currently has an average rating of “Buy” and an average target price of $47.54.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC purchased a new position in Hologic in the 3rd quarter valued at approximately $554,000. IFM Investors Pty Ltd purchased a new position in Hologic during the third quarter worth $335,000. Ladenburg Thalmann Financial Services Inc. increased its position in Hologic by 66.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock worth $458,000 after buying an additional 4,984 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in Hologic by 249.1% during the third quarter. Cubist Systematic Strategies LLC now owns 48,878 shares of the medical equipment provider’s stock worth $1,793,000 after buying an additional 34,877 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Hologic during the third quarter worth $39,041,000. 96.41% of the stock is owned by hedge funds and other institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.